Prevalence and determinants of selected cardio-metabolic risk factors among people living with HIV/AIDS and receiving care in the South West Regional Hospitals of Cameroon: a cross-sectional study

Roland Cheofor Ngu1,2,6,7*, Simeon-Pierre Choukem1,2,3, Christian Akem Dimala1,4, Julius N. Ngu5 and Gottlieb Lobe Monekosso2

Abstract

Objective: Metabolic disorders and cardiovascular risk factors are not routinely assessed in the care of HIV patients in developing countries, known to have the highest disease burden. We described the prevalence and factors associated with major cardio-metabolic risk factors (obesity, diabetes and hypertension) in HIV/AIDS patients.

Results: The prevalence of diabetes, hypertension and obesity were 11.3% (95% CI 8.10–15.43), 24.8% (95% CI 20.1–30.0) and 14.5% (95% CI 11.1–19.3) respectively. Central obesity and high alcohol intake were the factors significantly associated with diabetes mellitus, while central obesity and overweight/obesity were significantly associated with having hypertension. Short duration of antiretroviral therapy was the significant predisposing factor for obesity. On multivariate analyses, the only association observed was between central obesity and diabetes (Adjusted OR 2.52, 95% CI 1.01–6.30, \(P = 0.048\)). Conclusively, DM, HTN and obesity are highly prevalent in HIV/AIDS patients in the SWR hospitals of Cameroon, with that of DM and obesity being higher than that seen in the general population while that of HTN equaling that of the general population. Awareness of these data among clinicians involved in the management of these patients should be emphasized.

Keywords: Diabetes, Hypertension, Obesity, HIV/AIDS, Cameroon

Introduction

Although potent antiretroviral therapy has reduced human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)-related morbidity and mortality, concerns about treatment-related metabolic complications and cardiovascular diseases (CVD) have emerged [1]. These complications resemble metabolic and body composition abnormalities of the metabolic syndrome (MS) described with increasing frequency in the general adult population [2]. MS is a constellation of metabolic and physical abnormalities frequently associated with increased risk of insulin resistance and cardiovascular morbidity and mortality in the general population [2]. According to the new criteria of the international diabetic federation (IDF), MS is defined as the presence of central obesity plus any two of the four factors; raised triglycerides (TG) level, reduced high density lipoprotein cholesterol (HDL-c), raised blood pressure (BP) and raised fasting plasma glucose [3].

Studies conducted in developed nations so far, have provided information suggesting that certain combination antiretroviral therapy regimens, especially those that include protease inhibitors, are associated with elevated
serum triglycerides, total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-c) as well as insulin resistance. On the other hand, there has been little, or no effect observed on high density lipoprotein cholesterol. This dyslipidemia and insulin resistance are known to favour the development of atherosclerosis, thus potentially explaining the connection between highly active antiretroviral therapy (HAART) and adverse cardio-metabolic outcomes [4].

In sub-Saharan Africa (SSA), first-generation NRTIs are still widely recommended as first-line therapies in treatment protocols which report have shown to be associated with various adverse metabolic and cardiovascular effects [5, 6]. Furthermore, with the initiatives by governments to scale-up care for HIV/AIDS, several SSA countries, including Cameroon, now provide antiretroviral drugs free of charge [7]. Consequently, patients are increasingly being prescribed lifelong HAART and are therefore at risk of developing related metabolic disorders and premature CVD. Despite this, there is paucity of data in Africa, and Cameroon in particular, on the prevalence of these cardio-metabolic risk factors among HIV-infected patients. Thus, aim of this study, was to describe the prevalence and identify the risk factors of diabetes, hypertension and obesity among HIV/AIDS patients in the South West Regional Hospitals of Cameroon.

Main text

Methods

Study design, setting and population

The participants in this cross-sectional hospital-based study were patients living with HIV/AIDS and attending the treatment centers of the Buea and Limbe Regional hospitals in the South West Region of Cameroon. Activities in these centers include: HIV counseling and testing, education on lifestyle modification and diet, viral load and CD4 count tests to monitor the progress of the treatment, dispensation of antiretroviral drugs, education to ensure compliance to treatment and management of defaulters, and follow-up of opportunistic infections.

Study participants were recruited consecutively during their routine follow-up visits. They had to be aged 21 years or older and to sign an informed consent form to take part in the study.

Sample size

The sample size for this study was calculated using the online software www.openepi.com developed by Emory University, USA [8]. Based on previous prevalence, we assumed the highest prevalence of these 3 conditions will be 20% [9–11]. Our minimum sample size was 246 but we recruited 311 patients to improve the power of our results.

Data collection and definition of variables

Data on medical history, family history and risk factors of hypertension and diabetes were collected from recruited participants as self-reports except for their last CD4 count which was obtained from their medical records. Anthropometric and vital parameters measured included: height, weight, BP, waist circumference and fasting blood glucose (FBG). These parameters were assessed using standardized methods. FBG was done using a glucometer (GlucoDr super sensor-AGM-2200 allmedicus, code 2) and diabetes was defined by a FBG ≥ 126 mg/dl (using the American Diabetes Association criteria) [12] and/or a previous diagnosis of diabetes. The BP on each arm for each patient was measured twice using an electronic sphygmomanometer (Brand: DBPOWER) and the average systolic and diastolic BP for both arms were calculated. Hypertension was defined by an average systolic BP ≥ 140 or an average diastolic BP ≥ 90 [13] and/or a previous diagnosis of hypertension. BMI was calculated as; weight (kg)/height^2 (m^2). Obesity was defined as a BMI ≥ 30 kg/m^2 and overweight by a BMI between 25 and 29.9 kg/m^2 [14]. Excess alcohol intake was defined as alcohol consumption ≥ 21 units/week for men and ≥ 14 units/week for women [15], adequate exercise was defined as ≥ 30 min of moderate aerobic exercise for at least 3 times a week [16], central obesity was defined as a waist circumference ≥ 94 cm for males and ≥ 80 cm for females according to the IDF [3], short duration of HAART was taken as antiretroviral therapy use ≤ 60 months and low CD4 count defined as CD4 count ≤ 350 cells/mm^3.

Statistical analysis

Data were analyzed using Epi info™ version 7.1.1.14. Frequencies and means of socio-demographic and clinical characteristic of our participants were first obtained. Furthermore, we assessed associations between patient characteristics and, each of hypertension, obesity and diabetes using the Pearson's Chi squared tests or their non-parametric equivalents where appropriate. Statistical significance was set at a P value < 0.05. After that, to adjust for confounders, a multivariable logistic regression models were built for hypertension, diabetes and obesity incorporating all factors with a P value < 0.25 from the Chi squared test [17].

Results

Demographic and clinical characteristics of the study participants

Of the 311 participants recruited, 83.9% (261) were females. The participants’ clinical and demographic characteristics are presented on Table 1. Ages ranged from 22
to 73 years with a mean age of 43.4 ± 10.6 years. Three hundred and two participants (97%) were on HAART and the most frequently used regimen was Zidovudine–Lamivudine–Nevirapine (62.3%) (Table 1).

Prevalence and factors associated with diabetes
Among the 311 participants, 35 had diabetes corresponding to a prevalence of 11.3% (95% CI 8.1–15.4). Central obesity and a high alcohol intake were found to be significantly associated with diabetes on bivariate analysis (P = 0.03 and P = 0.03 respectively). On multivariate analyses, only central obesity remained weakly significantly associated with diabetes in these participants (Adjusted OR: 2.52, 95% CI 1.01–6.30, P = 0.048) (Table 2).

Prevalence and factors associated with hypertension
The prevalence of hypertension in our study population was 24.8% (95% CI 20.1–30.0). Patients with central obesity and overweight/obesity were more likely to have hypertension (P = 0.004 and P = 0.003 respectively). On multivariate analyses using logistic regressions, no factor was found to be significantly associated with hypertension (Table 3).

Prevalence and factors associated with obesity
The prevalence of obesity in our study population was 14.8% (95% CI 10.9–19.0), and that overweight was almost twice this prevalence (27%) (Table 1). The factor associated with obesity in bivariate analyses was shorter duration of ART (P = 0.040). On logistic regression, there was weak evidence of an association between long ART duration and obesity (adjusted OR: 2.40, 95% CI 1.00–5.75, P = 0.049) (Table 4).

Discussion
There is paucity of data on the potential association between HAART and cardio-metabolic risk factors in Africa. This study aimed to determine the prevalence and risk factors of hypertension, diabetes mellitus and obesity in HIV/AIDS patients in Cameroon and discuss them with reference to their equivalents in the general population. We found a significantly elevated prevalence of these CVD risk factors in our study population. The prevalence of diabetes, hypertension and obesity were as high as 11.3, 24.8 and 14.8% respectively in these major semi-urban settings of the South West Region of Cameroon.

Table 1 Socio-demographic characteristics of the study population (n = 311)

| Characteristic               | Total (n = 311) | Females (n = 261) | Males (n = 50) | P* |
|-----------------------------|----------------|-------------------|---------------|----|
| Age in years, mean (± SD)   | 43.4 (± 10.6)  | 41.7 (± 10.6)     | 45.9 (± 10.4) | 0.010 |
| Age, years                  |                |                   |               | 0.220 |
| ≤ 45                        | 197 (63.3%)    | 169 (64.8%)       | 28 (56%)      | 0.620 |
| > 45                        | 114 (36.7%)    | 92 (35.2%)        | 22 (44%)      | 0.620 |
| BMI, mean (kg/m²)           | 25.0 (± 4.7)   | 25.2 (± 4.8)      | 23.8 (± 3.7)  | 0.047 |
| BMI categories (kg/m²)      |                |                   |               | 0.580 |
| < 25                        | 182 (58.5%)    | 158 (62.5%)       | 24 (48%)      | 0.047 |
| ≥ 25 to < 30                | 84 (27%)       | 70 (27%)          | 14 (28%)      | 0.047 |
| ≥ 30                        | 45 (14.5%)     | 41 (15.7%)        | 4 (8.0%)      | 0.047 |
| HAART combinations (n = 302)|                |                   |               | 0.128 |
| AZT + 3TC + EFV             | 10 (3.3%)      | 7 (7.0%)          | 3 (30%)       | 0.128 |
| AZT + 3TC + NVP             | 189 (61.6%)    | 164 (86.5%)       | 25 (13.5%)    | 0.032 |
| AZT + 3TC + NVP + TFV       | 1 (0.3%)       | 1 (100%)          | 0 (0%)        | 0.032 |
| TFV + 3TC + EFV             | 71 (23.5%)     | 54 (76.1%)        | 17 (23.9%)    | 0.032 |
| TFV + 3TC + LPV + IDV       | 1 (0.3%)       | 1 (100%)          | 0 (0%)        | 0.032 |
| TFV + 3TC + NVP             | 28 (9.3%)      | 25 (89.3%)        | 3 (10.7%)     | 0.032 |
| D4T + 3TC + NVP             | 2 (0.7%)       | 1 (50%)           | 1 (50%)       | 0.032 |
| CD4 count, mean (cell/mm³)  | 470.5 (± 260)  | 484.4 (± 266.8)   | 398 (± 208.5) | 0.032 |
| CD4 count, cell/mm³         |                |                   |               | 0.060 |
| CD4 count ≤ 350             | 95 (30.9%)     | 74 (77.9%)        | 11 (22.1%)    | 0.060 |
| CD4 count > 350             | 216 (69.1%)    | 187 (22.1%)       | 29 (78%)      | 0.060 |

AZT zidovudine, 3TC lamivudine, EFV efavirenz, TDF tenofovir, IDV indinavir, D4T stavudine, LPV lopinavir, BMI body mass index, SD standard deviation
* P value for comparison between males and females; data are presented as mean ± SD or counts (%)
* P value after fisher’s exact test
The observed prevalence of diabetes in our study population is significantly higher than the 4.9% estimated national prevalence of diabetes mellitus in the Cameroonian general population in 2013 [18]. This could suggest that HIV/AIDS patients are more likely to develop this CVD risk factor compared to the general population, with possible explanations to this finding being the reported effects of the chronic HIV infection, prolonged antiretroviral therapy, or simply differences in the clinical and socio-demographic characteristics of the study populations. Chronic HIV infection has been reported to contribute to insulin resistance and diabetes by up-regulating inflammatory chemokines involved in insulin regulation [19–21]. Likewise, antiretroviral therapy has increasingly been suggested to contribute to hyperglycemia and diabetes mellitus [20]. Nevertheless, we found no association between HAART use, prolonged duration of therapy and diabetes. Insufficient data from the former study hinders the assessment of differences in socio-demographic and clinical characteristics between the study populations as potential reasons the observed difference in the prevalence of diabetes. Central obesity, which is a known risk factor for insulin resistance was the only factor found to be significantly associated with

| Table 2 | Risk factors for diabetes in 311 HIV/AIDS patients |
|------------------------|-----------------------------|-----------------|------------------|-----------------|------------------|
| Risk factors for diabetes mellitus | Participants (n = 311) | Diabetes | Unadjusted OR (95% CI) | P value | Adjusted odds ratio (95% CI) | P value* |
| Age in years | | | | | | |
| > 45 | 114 | 13 (11.4%) | 0.98 (0.47–2.02) | 0.95 | – |
| ≤ 45 | 197 | 22 (11.2%) | 1 (Ref) | | |
| Gender | | | | | | |
| Male | 50 | 7 (14%) | 1.36 (0.56–3.30) | 0.50 | – |
| Female | 261 | 28 (10.7%) | 1 (Ref) | | |
| Body mass index | | | | | | |
| Overweight/obesity | 129 | 18 (14%) | 0.64 (0.31–1.29) | 0.21 | 0.95 (0.41–2.21) | 0.898 |
| Normal/underweight | 182 | 17 (9.3%) | 1 (Ref) | 1 (Ref) |
| Central obesity | | | | | | |
| Yes | 170 | 25 (14.7%) | 0.44 (0.21–0.96) | 0.03 | 2.52 (1.01–6.30) | 0.048 |
| No | 141 | 10 (7.1%) | 1 (Ref) | 1 (Ref) |
| Exercise | | | | | | |
| Adequate | 16 | 3 (18.8%) | 1.90 (0.51–7.02) | 0.33 | – |
| Inadequate | 295 | 32 (10.9%) | 1 (Ref) | | |
| Alcohol intake | | | | | | |
| Alcoholics | 9 | 3 (33.3%) | 4.22 (1.01–17.69) | 0.03 | 0.27 (0.06–1.21) | 0.086 |
| Non alcoholics | 302 | 32 (10.6%) | 1 (Ref) | 1 (Ref) |
| Smoking | | | | | | |
| Yes | 4 | 1 (25%) | 0.37 (0.04–3.69) | 0.38 | – |
| No | 307 | 34 (11.1%) | 1 (Ref) | | |
| ART | | | | | | |
| Yes | 302 | 34 (11.3%) | 1.02 (0.12–8.37) | 0.99 | – |
| No | 9 | 1 (11.1%) | 1 (Ref) | | |
| ART duration (months) | | | | | | |
| Long duration | 88 | 10 (11.4%) | 1 (Ref) | 0.97 | – |
| Short duration/Nil | 223 | 25 (11.2%) | 1 (Ref) | | |
| CD4 count (cells/mm³) | | | | | | |
| ≤ 350 | 95 | 12 (12.6%) | 0.82 (0.39–1.73) | 0.61 | – |
| > 350 | 216 | 23 (10.7%) | 1 (Ref) | | |
| Family history | | | | | | |
| Yes | 62 | 8 (12.9%) | 1.21 (0.52–2.82) | 0.65 | – |
| No | 248 | 27 (10.9%) | 1 (Ref) | | |

Ref/Reference group

* P value = the P value after adjusting for the other factors in Multivariate logistic regression analysis
diabetes in our study population. Central obesity is particularly important in patients on antiretroviral therapy since several drug classes are known to induce a redistribution of body fats with predominant central and visceral deposition [22–25]. Despite the higher prevalence of diabetes among these patients compared to the general population, it is worth noting that a similar prevalence (11.5%) was reported in the United States of America, in patients of different origin from those of our study [26]. An even higher prevalence of diabetes among these patients was found in the study by Diouf et al. (14.5%). The participants in that study, however, had been on HAART for a much longer duration with predominantly protease inhibitor regimens [27].

We recorded a prevalence of hypertension in HIV/AIDS patients similar to that earlier reported in the general population in Cameroon (24.6%) in 2003 in the CamBod study [28]. The chronic inflammatory state following infection with HIV has been reported to result in vasculitis, aneurysms of large vessels, impaired renal flow, renal failure, all contributing to the development of hypertension [29]. This prevalence of hypertension is similar to that reported by Ekali et al. in Cameroon [30]. Similarities in study designs, settings and participants

| Risk factors for diabetes mellitus | Participants (n = 311) | HTN | Unadjusted OR (95% CI) | P value | Adjusted odds ratio (95% CI) | P* |
|----------------------------------|-----------------------|-----|------------------------|---------|-----------------------------|-----|
| Age in years                     |                       |     |                        |         |                             |     |
| > 45                             | 114                   | 34  | (29.8%)                | 0.66    | (0.39–1.11)                 | 0.12|
| ≤ 45                             | 197                   | 43  | (21.8%)                | 1 (Ref) | 1 (Ref)                     |     |
| Gender                           |                       |     |                        |         |                             |     |
| Male                             | 50                    | 12  | (24%)                  | 0.95    | (0.47–1.93)                 | 0.89|
| Female                           | 261                   | 65  | (24.9%)                |         |                             |     |
| Body mass index                  |                       |     |                        |         |                             |     |
| Overweight                       | 129                   | 43  | (33.3%)                | 0.46    | (0.27–0.78)                 | 0.003|
| Normal/underweight               | 182                   | 34  | (18.7%)                | 1 (Ref) | 1 (Ref)                     |     |
| Central obesity                  |                       |     |                        |         |                             |     |
| Yes                              | 170                   | 53  | (31.2%)                | 0.45    | (0.26–0.78)                 | 0.004|
| No                               | 141                   | 24  | (17.0%)                | 1 (Ref) | 1 (Ref)                     |     |
| Exercise                         |                       |     |                        |         |                             |     |
| Adequate                         | 16                    | 3   | (18.8%)                | 0.69    | (0.19–2.49)                 | 0.57|
| Inadequate                       | 295                   | 74  | (25.1%)                | 1 (Ref) | 1 (Ref)                     |     |
| Alcohol intake                   |                       |     |                        |         |                             |     |
| Alcoholic                        | 9                     | 2   | (22.2%)                | 0.87    | (0.18–4.25)                 | 0.86|
| Non Alcoholics                   | 302                   | 75  | (24.8%)                | 1 (Ref) | 1 (Ref)                     |     |
| Smoking                          |                       |     |                        |         |                             |     |
| Yes                              | 4                     | 2   | (50%)                  | 3.09    | (0.43–22.34)                | 0.24|
| No                               | 307                   | 75  | (24.4%)                |         |                             |     |
| ART                              |                       |     |                        |         |                             |     |
| Yes                              | 302                   | 76  | (25.2%)                | 2.69    | (0.33–21.86)                | 0.34|
| No                               | 9                     | 1   | (11.1%)                | 1 (Ref) | 1 (Ref)                     |     |
| ART duration (months)            |                       |     |                        |         |                             |     |
| Long duration                    | 88                    | 26  | (29.6%)                | 1.41    | (0.81–2.46)                 | 0.22|
| Short duration/Nil               | 223                   | 51  | (22.9%)                | 1 (Ref) | 1 (Ref)                     |     |
| CD4 count (cells/mm³)            |                       |     |                        |         |                             |     |
| ≤ 350                            | 95                    | 25  | (26.3%)                | 0.89    | (0.51–1.54)                 | 0.67|
| > 350                            | 216                   | 52  | (24.1%)                | 1 (Ref) | 1 (Ref)                     |     |
| Family history                   |                       |     |                        |         |                             |     |
| Yes                              | 127                   | 37  | (29.1%)                | 1.48    | (0.88–2.49)                 | 0.14|
| No                               | 184                   | 40  | (21.7%)                | 1 (Ref) | 1 (Ref)                     |     |

* P value = the P value after adjusting for the other factors in Multivariate logistic regression analysis
probably explain these similar findings. Malaza et al. [11] in rural South-Africa who enrolled younger participants compared to ours, reported a lower prevalence of hypertension (19.5%). On the other hand, Gazzaruso et al. who had all HIV/AIDS participants on treatment, estimated a much higher prevalence of hypertension among these HIV/AIDS participants at 34.2% [31]. As earlier reported, we also observed higher proportions of hypertension with increasing BMI. Despite the significant association noted between BMI, central obesity and hypertension at bivariate levels of analysis, these associations were lost after controlling for other confounders, confirming the multifactorial etiology of this important CVD risk factor. Unlike the prevalence of hypertension in our study which was similar to that of the general population, that of obesity, as defined by the BMI, was higher than that of the general population (9.6%) [32]. A similar prevalence of obesity (14%) was found by Amorosa et al. in a study in Philadelphia [33], however, lower values have been reported in settings similar to ours such as in the study by Muhammad et al. (6.5%) in Nigeria [34]. In addition to HAART, raised CD4 count levels have been reportedly associated with obesity in previous studies [27].

As our study has shown, the prevalence of HTN, obesity and DM is high amongst HIV/AIDS patients. This should inform the health policy, clinical practice and well as HIV research to target these diseases in HIV patients in Cameroon and internationally which could be in the form of passing a policy to be implemented in the health system by clinicians or other health care providers as well as routine screening and monitoring of these conditions in HIV patients. In addition, more robust evidence research such as systematic review should be carried out to ascertain the Global burden of these diseases in HIV patients.

### Conclusion

The prevalence of diabetes mellitus, hypertension and obesity in HIV patients in the South West Regional (SWR) Hospitals of Cameroon is high, with that of diabetes and obesity being higher than in the general population and that of hypertension equally that of the general population. Central obesity the only factor found to be marginally associated with diabetes. Awareness of these rising trends in these CVD risk factors in HIV/AIDS patients among clinicians is important in patient monitoring and management.

| Risk factors for obesity | Total participants (n=311) | Obese | Unadjusted OR (95% CI) | P value | Adjusted odds ratio (95% CI) | P value* |
|--------------------------|-----------------------------|-------|------------------------|---------|-------------------------------|---------|
| Age                      |                             |       |                        |         |                               |         |
| > 45 years               | 114                         | 13 (11.4%) | 0.66 (0.33–1.32)       | 0.24    | 0.81 (0.39–1.69)              | 0.573   |
| ≤ 45 years               | 197                         | 32 (16.2%) | 1 (Ref)                | 0.16    | 2.33 (0.78–6.94)              | 0.130   |
| Gender                   |                             |       |                        |         |                               |         |
| Male                     | 50                          | 4 (8%) | 2.14 (0.73–6.28)       | 1 (Ref) | 1 (Ref)                       |         |
| Female                   | 261                         | 41 (15.7%) | 1 (Ref)               | 1 (Ref) |                               |         |
| Exercise                 |                             |       |                        |         |                               |         |
| Adequate                 | 16                          | 2 (12.5%)  | 1.19 (0.26–5.44)      | 0.82    |                               | –       |
| Inadequate               | 295                         | 3 (14.6%)  | 0.32 (0.08–1.34)      | 0.10    | 0.26 (0.06–1.15)              | 0.075   |
| Alcohol intake           |                             |       |                        |         |                               |         |
| Alcoholics               | 9                           | 3 (33.3%)  | 2.14 (0.73–6.28)      | 0.16    | 2.33 (0.78–6.94)              | 0.130   |
| Non alcoholics           | 302                         | 42 (13.9%) | 1 (Ref)               | 1 (Ref) |                               |         |
| ART duration (months)    |                             |       |                        |         |                               |         |
| Long duration (61–216)   | 88                          | 7 (8%) | 2.38 (1.02–5.55)      | 0.04    | 2.40 (1.00–5.75)              | 0.049   |
| Short duration/Nil (0–60)| 223                         | 38 (17.1%) | 1 (Ref)               | 1 (Ref) |                               |         |
| CD4 count                |                             |       |                        |         |                               |         |
| ≤ 350 cells/mm³          | 95                          | 12 (12.6%) | 0.80 (0.39–1.63)    | 0.54    |                               | –       |
| > 350 cells/mm³          | 216                         | 33 (15.3%) | 1 (Ref)               | 1 (Ref) |                               |         |
| ART                      |                             |       |                        |         |                               |         |
| Yes                      | 302                         | 43 (14.2%) | 1.72 (0.35–8.56)    | 0.50    |                               | –       |
| No                       | 9                           | 2 (22.2%)  | 1 (Ref)               | 1 (Ref) |                               |         |

**ART** antiretroviral therapy

* P value = the P value after adjusting for the other factors in Multivariate logistic regression analysis
Limitations
The interpretation of our results must, nevertheless, take into account some limitations among which the cross-sectional design of the study that hinders inferences on causality and the reliance on single BP and glucose measurements to ascertain disease status. Despite these limitations, this study remains an important contribution to the scanty literature on this topic by providing baseline epidemiological data for future research and health policy formulation.

Abbreviations
AIDs: acquired immunodeficiency syndrome; BMI: body mass index; BP: blood pressure; CD4: cluster of differentiation; CVD: cardiovascular disease; DM: diabetes mellitus; FBG: fasting blood glucose; HAART: highly active antiretroviral therapy; HDL-c: high density lipoprotein cholesterol; HIV: human immunodeficiency virus; HTN: hypertension; IDF: international diabetic federation; LDL-c: low-density lipoprotein cholesterol; MS: metabolic syndrome; NRTIs: nucleotide reverse transcriptase inhibitors; OR: odds ratio; SSA: sub-Saharan Africa; SWR: South West Region; TC: total cholesterol; TG: triglycerides.

Authors’ contributions
RN, SC, JN and ML conceived, designed and carried out this work. RN and DA conducted the data analyses and interpretation. NC drafted the work and all authors reviewed the manuscript and revised it critically for important intellectual content, gave final approval of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy of integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Author details
1 Health and Human Development (2HD) Research Network, Douala, Cameroon. 2 Department of Internal Medicine and Pediatrics, Faculty of Health Sciences, University of Buea, Buea, Cameroon. 3 Diabetes and Endocrinology Unit, Department of Internal Medicine, Douala General Hospital, Douala, Cameroon. 4 Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. 5 University of Alabama at Birmingham, Birmingham, USA. 6 Nuffield Department of Medicine, University of Oxford, Oxford, UK. 7 World Health Organization Headquarters, Geneva, Switzerland.

Acknowledgements
We thank study participants, the staffs of the treatment centers of the Regional Hospitals of Buea and Limbe as well as the Faculty of Health Sciences of the University of Buea. I wish to thank my parents, my siblings and Mbong Roland for their immense support to this research project.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Consent for publication
Not applicable.

Ethical approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board of the Faculty of Health Sciences, University of Buea, Cameroon (Ref. 2013/13B UB/ FHS/IRB) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. All participants were adequately explained what the study was about and we made sure they understood adequately the benefits and the harms. We then presented them with a consent form containing a summary of the research in plain language, benefits and harms that may occur and a free will to opt in and out at any time during the study for them to sign.

Funding
This research was entirely self-funded.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 17 January 2018 Accepted: 11 May 2018
Published online: 16 May 2018

References
1. Jericó C, Knobel H, Montero M, Ordoñez-Llanos J, Guiral A, Gimeno JL, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;28:132–7.
2. Sobieszczyn ME, Hoover DR, Anastas K, Mulligan K, Tan T, Shi Q, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr. 2008;48:272–80.
3. IDWF World Definition of the Metabolic Syndrome [Internet]. [cited 2014 Mar 18]. http://www.idf.org/metabolic-syndrome.
4. Kiage JN, Heinbürger DC, Nyirenda CK, Welfons MF, Bagchi S, Chi BH, et al. Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids Health Dis. 2013;12:50.
5. Brown TT, Li X, Cole SR, Kingsley LA, Paaleja FJ, Riddell SA, et al. Cumulative exposure to nuleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19:1375–83.
6. Fleischman A, Johnson S, Systrom DM, Hrovat M, Fanar CT, Frontera W, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007;292:E1666–73.
7. Boyer S, Koulia-Shiro S, Abé C, Sire B, Moatti J-P. Implementing operational research to scale-up access to antiretroviral therapy for HIV infection: lessons learned from the Cameroonian experience. Curr Opin HIV AIDS. 2011;6:239–44.
8. Dean A, Sullivan K, Soe M. OpenEpiphi Open Source Epidemiologic Statistics for Public Health Version. www.OpenEpi.com [Internet]. 2013 [cited 2018 Feb 5]. http://www.openepi.com/Menu/OE_Menu.htm.
9. Malaza A, Mossong J, Bargnighausen T, Newell M-L. Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa. PLoS ONE. 2012;7:e47761.
10. Jericó C, Knobel H, Montero M, Ordoñez-Llanos J, Guiral A, Gimeno JL, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;28:132–7.
11. Shen Y, Wang Z, Lu L, Zhang R, Zheng Y, Lu H. Prevalence of hypertension and obesity in adults with newly diagnosed HIV/AIDS in China. BMC Infect Dis. 2013;13:79.
12. Standards of Medical Care in Diabetes—2011. Diabetes Care. 2011;34:S1–61.
13. Verdecchia P, Angeli F, Verdecchia P, Angeli F. The Seventh Report of the Joint National Committee on the prevention, detection, evaluation and treatment of high blood pressure: the weapons are ready. Rev Esp Cardiol. 2003;56:843–7.
14. WHO. Global database on body mass index [Internet]. [cited 2017 Feb 11]. http://apps.who.int/bmi/index.jsp.
15. Topiwala A, Allan CL, Valkanova V, Zsoldos E, Filippini N, Sexton C, et al. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. BMJ. 2017;357:j2533.
16. IDF type 2 diabetes management guidelines lifestyle diet exercise[NDI] [Internet]. [cited 2018 Feb 5]. http://www.ndi.org/international-diabe tes-federation-guidelines-lifestyle-physical-activity-exercise-diet-type-2-diabetes.aspx.html.
17. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.
18. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49.
19. Araujo S, Bahlon S, Machuca I, Moreno A, Pérez-Elías MJ, Casado JL. Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs. Eur J Endocrinol. 2014;171:545–54.
20. Hadigan C, Kattakuzhy S. Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus. Endocrinol Metab Clin North Am. 2014;43:685–96.
21. Warinner AH, Burkholder GA, Overton ET. HIV-related metabolic comorbidities in the current ART era. Infect Dis Clin North Am. 2014;28:457–76.
22. Bogner JR, Vielhauer V, Beckmann RA, Michl G, Wille L, Salzberger B, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:237–44.
23. Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallo‑las J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592–8.
24. Rakotoambinina R, Médioni J, Rabian C, Jubiault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr. 2001;27:443–9.
25. van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847–55.
26. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–12.
27. Diouf A, Courmial A, Ba-Fall K, Ngom-Guèye NF, Eymard-Duvernay S, Ndiaye I, et al. Diabetes and hypertension among patients receiving antiretroviral treatment since 1998 in Senegal: prevalence and associated factors. ISRN AIDS. 2012:2012:621565.
28. Kamandjeu RM, Edwards R, Atanga JS, Kiawi EC, Unwin N, Mbanya J-C. Anthropometry measures and prevalence of obesity in the urban adult population of Cameroon: an update from the Cameroon Burden of Diabetes Baseline Survey. BMC Public Health. 2006;6:228.
29. Aoun S, Ramos E. Hypertension in the HIV-infected patient. Curr Sci. 2000;2:478–81.
30. Ekali LG, Johnstone LK, Echouffo-Tcheugui JB, Kounfack C, Dehayem MY, Fezeu L, et al. Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in Cameroonian receiving first-line antiretroviral treatment. Diabetes Metab. 2013;39:71–7.
31. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003;21:1377–82.
32. Cameroon Obesity—adult prevalence rate—Demographics [Internet]. [cited 2017 Mar 4]. http://www.indexmundi.com/cameroun/obesity_adult_prevalence_rate.html.
33. Amorosa V, Synnestvedt M, Gross R, Friedman H, MacGregor RR, Gudonis D, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39:557–61.